^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1d
    Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study. (PubMed, Lancet Haematol)
    These results demonstrate that model-based ATG dosing promotes robust CD4+ immune reconstitution after ex vivo CD34+ selected allogeneic HCT, underscoring the potential of pharmacokinetically guided ATG as a strategy to optimise immune recovery in myeloablative, calcineurin inhibitor-free transplantation for haematological malignancies.
    P2 data • Preclinical • Journal
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    1d
    Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Sep 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301)
    2d
    Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics (clinicaltrials.gov)
    P1, N=36, Recruiting, medac GmbH | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    fludarabine IV • Grafapex (treosulfan)
    2d
    Modified Conditioning Regimen for CML-BP (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    melphalan • fludarabine IV • thiotepa
    2d
    Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    2d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim)
    2d
    T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (clinicaltrials.gov)
    P1, N=36, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Site plans to become a site for a multicenter study of this therapy
    Trial termination • IO biomarker
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Zuplenz (ondansetron oral dispersible film)
    3d
    CARLYSE: Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=18, Recruiting, Autolus Limited | N=12 --> 18
    Enrollment change
    |
    cyclophosphamide • fludarabine IV • Aucatzyl (obecabtagene autoleucel)
    3d
    SEEK: Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease (clinicaltrials.gov)
    P1, N=36, Recruiting, The Children's Hospital of Zhejiang University School of Medicine | N=72 --> 36
    Enrollment change
    |
    cyclophosphamide • fludarabine IV
    3d
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=11, Terminated, The First Affiliated Hospital with Nanjing Medical University | N=33 --> 11 | Trial completion date: Jun 2028 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jun 2025; Achieve the proof of concept.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    6d
    Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P1, N=6, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Trial primary completion date: Aug 2025 --> Dec 2026
    Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    7d
    Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 19 | Trial completion date: Mar 2043 --> Jul 2040 | Trial primary completion date: Mar 2027 --> Aug 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)